Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec 1;40(12):e507-e509.
doi: 10.1097/INF.0000000000003263.

Safety and Tolerability of Monoclonal Antibody Therapies for Treatment of COVID-19 in Pediatric Patients

Gregory Mak  1   2 , Aimee M Dassner  3 , Benjamin M Hammer  3 , Benjamin R Hanisch  2   4
Affiliations

Safety and Tolerability of Monoclonal Antibody Therapies for Treatment of COVID-19 in Pediatric Patients

Gregory Mak et al. Pediatr Infect Dis J. .

Erratum in

Abstract

There is a little data regarding safety or efficacy of monoclonal antibody treatment for mild-to-moderate COVID-19 in pediatric patients despite it being frequently used in adults. This retrospective study of 17 patients with mild-to-moderate COVID-19 who received monoclonal antibody therapy found that the treatment was well tolerated, safe, and may be effective in halting progression to severe disease.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to disclose.

References

    1. CDC. COVID Data Tracker 2021. Available at: https://covid.cdc.gov/covid-data-tracker/#datatracker-home2021. Accessed April 20, 2021.
    1. DeBiasi RL, Song X, Delaney M, et al. . Severe coronavirus disease-2019 in children and young adults in the Washington, DC, metropolitan region. J Pediatr. 2020;223:199–203 e191. - PMC - PubMed
    1. Feldstein LR, Tenforde MW, Friedman KG, et al. ; Overcoming COVID-19 Investigators. Characteristics and outcomes of US children and adolescents with multisystem inflammatory syndrome in children (MIS-C) compared with severe acute COVID-19. JAMA. 2021;325:1074–1087. - PMC - PubMed
    1. Chen P, Nirula A, Heller B, et al. ; BLAZE-1 Investigators. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19. N Engl J Med. 2021;384:229–237. - PMC - PubMed
    1. Gottlieb RL, Nirula A, Chen P, et al. . Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA. 2021;325:632–644. - PMC - PubMed

Publication types

MeSH terms

Substances